Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptinyx Inc (NQ: APTX )

0.4200 +0.0145 (+3.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptinyx Inc

< Previous 1 2 3 4 5 Next >
Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) rose 41.5% to $0.3255 in pre-market trading after gaining 8% on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Tuesday Morning Shares Are Trading Lower By 38%; Here Are 31 Stocks Moving Premarket
Gainers Neptune Wellness Solutions Inc. (NASDAQ: NEPT) shares rose 106.9% to $0.5482 in pre-market trading on heavy volume. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
From Aptinyx Inc.
Via Business Wire
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
From Aptinyx Inc.
Via Business Wire
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
From Aptinyx Inc.
Via Business Wire
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Aptinyx Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
From Aptinyx Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
  
Via Benzinga
What 4 Analyst Ratings Have To Say About Aptinyx
  Over the past 3 months, 4 analysts have published their opinion on Aptinyx (NASDAQ:APTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
Aptinyx Shares Plummet As Mid-Stage Fibromyalgia Study Missed Primary Endpoint
Aptinyx Inc. (NASDAQ: APTX) announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia. The Phase 2b clinical study was designed to evaluate the... 
Via Benzinga
Here's Why Aptinyx Stock Is Lower By Over 30% Friday
Aptinyx Inc (NASDAQ: APTX) shares are trading lower by 35.80% to $0.39 Friday morning after the company announced results from its Phase 2b Study of NYX-2925 did not achieve the primary endpoint. What... 
Via Benzinga
Aptinyx's Chronic Pain Candidate Fails To Top Placebo In Mid-Stage Study
Aptinyx Inc (NASDAQ: APTX) has announced results from a Phase 2b study evaluating the effects of NYX-2925 in patients with fibromyalgia, characterized by muscular or musculoskeletal pain with stiffness... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
From Aptinyx Inc.
Via Business Wire
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.